In cells with low RAS activity, such as wild-type RAS, BRAFV600E melanoma cells, there is synergy between type I1⁄2 RAF inhibitors (e.g., dabrafenib or encorafenib) and MEK inhibitors (trametinib or binimetinib). Here, RAF1 is linked to melanoma.